Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy
Acta cir. bras
;
34(12): e201901207, 2019. graf
Article
in English
| LILACS
| ID: biblio-1054689
ABSTRACT
Abstract In the muscle invasive bladder cancer (MIBC) standard of care treatment only patients presenting a major pathological tumor response are more likely to show the established modest 5% absolute survival benefit at 5 years after cisplatin-based neoadjuvant chemotherapy (NAC). To overcome the drawbacks of a blind NAC (i.e. late cystectomy with unnecessary NAC adverse events) with potential to survival improvements, preclinical models of urothelial carcinoma have arisen in this generation as a way to pre-determine drug resistance even before therapy is targeted. The implantation of tumor specimens in the chorioallantoic membrane (MCA) of the chicken embryo results in a high-efficiency graft, thus allowing large-scale studies of patient-derived "tumor avatar". This article discusses a novel approach that exploits cancer multidrug resistance to provide personalized phenotype-based therapy utilizing the MIBC NAC dilemma.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Urinary Bladder Neoplasms
/
Carcinoma
/
Urothelium
/
Chorioallantoic Membrane
/
Neoplasms, Experimental
Limits:
Animals
/
Humans
Language:
English
Journal:
Acta cir. bras
Journal subject:
General Surgery
/
Procedimentos Cir£rgicos Operat¢rios
Year:
2019
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Instituto do Câncer Arnaldo Vieira de Carvalho/BR
/
UNICAMP/BR
/
Universidade de Campinas/BR
Similar
MEDLINE
...
LILACS
LIS